-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Sino Biopharmaceutical Limited (HKG:1177) Insiders Placed Bullish Bets Worth CN¥41m in the Last 12 Months
Sino Biopharmaceutical Limited (HKG:1177) Insiders Placed Bullish Bets Worth CN¥41m in the Last 12 Months
Quite a few insiders have dramatically grown their holdings in Sino Biopharmaceutical Limited (HKG:1177) over the past 12 months. An insider's optimism about the company's prospects is a positive sign.
Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.
View our latest analysis for Sino Biopharmaceutical
Sino Biopharmaceutical Insider Transactions Over The Last Year
The Founder & Senior Vice Chairman Ping Tse made the biggest insider purchase in the last 12 months. That single transaction was for HK$29m worth of shares at a price of HK$5.79 each. That means that even when the share price was higher than HK$4.01 (the recent price), an insider wanted to purchase shares. Their view may have changed since then, but at least it shows they felt optimistic at the time. We always take careful note of the price insiders pay when purchasing shares. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.
In the last twelve months Sino Biopharmaceutical insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
SEHK:1177 Insider Trading Volume September 12th 2022There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).
Insider Ownership
For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Sino Biopharmaceutical insiders own about HK$27b worth of shares (which is 36% of the company). This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
So What Do The Sino Biopharmaceutical Insider Transactions Indicate?
It doesn't really mean much that no insider has traded Sino Biopharmaceutical shares in the last quarter. However, our analysis of transactions over the last year is heartening. It would be great to see more insider buying, but overall it seems like Sino Biopharmaceutical insiders are reasonably well aligned (owning significant chunk of the company's shares) and optimistic for the future. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
But note: Sino Biopharmaceutical may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
相当多的内部人士戏剧性地增持了中国生物制药有限公司(HKG:1177)过去12个月。一位内部人士对公司前景的乐观态度是一个积极的迹象。
尽管我们不认为股东应该简单地跟踪内幕交易,但从逻辑上讲,你应该关注内部人士是在买入还是卖出股票。
查看我们对中国生物制药的最新分析
中国生物制药过去一年的内幕交易
创始人兼高级副主席谢平进行了过去12个月来最大的内幕收购。这一笔交易是以每股5.79港元的价格购入价值2900万港元的股票。这意味着,即使股价高于4.01港元(最近的价格),也有内部人士想要购买股票。自那以后,他们的观点可能发生了变化,但至少这表明他们当时感到乐观。我们总是仔细注意内部人士购买股票时支付的价格。一般来说,当内部人士以高于当前价格的价格购买股票时,它会吸引我们的注意,因为这表明他们认为这些股票值得购买,即使是以更高的价格。
在过去的12个月里,中国生物制药的内部人士在买入股票,但没有卖出。你可以在下面看到过去12个月(由公司和个人)进行的内幕交易的直观描述。如果你点击图表,你可以看到所有的个人交易,包括股票价格、个人和日期!
联交所:2022年9月12日内幕交易量1177内部人士总是在买入大量股票。因此,如果这适合你的风格,你可以逐一检查每一种库存,或者你可以看看这个免费公司名单。(提示:内部人士一直在买入这些股票)。
内部人持股
对于一个普通股股东来说,公司内部人士持有多少股份值得一查。我认为,如果内部人士持有该公司大量股份,这是一个好兆头。中国生物制药内部人士持有价值约270亿港元的股份(占公司股份的36%)。这种由内部人士持有的重大所有权通常确实增加了公司以所有股东的利益运营的机会。
那么,中国生物制药内幕交易意味着什么呢?
上个季度没有内部人士交易中国生物制药的股票,这并不意味着什么。然而,我们对过去一年交易的分析令人振奋。看到更多的内部人士收购固然不错,但总的来说,中国生物制药的内部人士似乎相当一致(持有该公司相当大一部分股份),并对未来持乐观态度。如果你像我一样,你可能会想一想这家公司是会增长还是会萎缩。幸运的是,你可以检查这个免费显示分析师对其未来预测的报告。
但请注意:中国生物制药可能不是最值得买入的股票。所以让我们来看看这个免费高净资产收益率和低负债的有趣公司名单。
就本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前负责公开市场交易和私人处置,但不包括衍生品交易。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧